| Scott A Jenkinson, DO | |
|
55 Hospital Dr, Athens, OH 45701-2302 | |
| (740) 566-4530 | |
| (740) 566-4535 |
| Full Name | Scott A Jenkinson |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 41 Years |
| Location | 55 Hospital Dr, Athens, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265425698 | NPI | - | NPPES |
| 0753591 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0101X | Pathology - Anatomic Pathology | 34.003705 (Ohio) | Secondary |
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 34003705 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ohiohealth O'bleness Hospital | Athens, OH | Hospital |
| Hocking Valley Community Hospital | Logan, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ohiohealth Corporation | 6305758426 | 1900 |
News Archive
Health pioneers BetterYou have welcomed new guidance by the National Institute for Health and Care Excellence (NICE) highlighting that many adults in Britain have low levels of vitamin D and that some exposure to sunlight can help to build this up.
Common anti-cholesterol drugs show promise for reducing the risk of Alzheimer's disease, a University of Southern California-led study of Medicare data reveals.
This study used U.S. population data to identify changes in the supply of primary care physicians across counties from 2005 to 2015 and the association with life expectancy and other outcomes.
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
Results from a study conducted by Majestic Research suggest that Bristol Myers Squibb's Orencia, Johnson & Johnson's Remicade, and Amgen's/Wyeth's Enbrel will forfeit share of the rheumatoid arthritis market to Roche's newly launched Actemra. Early switching data from Majestic's proprietary panel of rheumatologists indicates that Orencia may be the biggest loser of all, as 54% of switches to Actemra thus far have been from Orencia.
› Verified 8 days ago
| Entity Name | Ohiohealth Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578545273 PECOS PAC ID: 6305758426 Enrollment ID: O20031105000532 |
News Archive
Health pioneers BetterYou have welcomed new guidance by the National Institute for Health and Care Excellence (NICE) highlighting that many adults in Britain have low levels of vitamin D and that some exposure to sunlight can help to build this up.
Common anti-cholesterol drugs show promise for reducing the risk of Alzheimer's disease, a University of Southern California-led study of Medicare data reveals.
This study used U.S. population data to identify changes in the supply of primary care physicians across counties from 2005 to 2015 and the association with life expectancy and other outcomes.
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
Results from a study conducted by Majestic Research suggest that Bristol Myers Squibb's Orencia, Johnson & Johnson's Remicade, and Amgen's/Wyeth's Enbrel will forfeit share of the rheumatoid arthritis market to Roche's newly launched Actemra. Early switching data from Majestic's proprietary panel of rheumatologists indicates that Orencia may be the biggest loser of all, as 54% of switches to Actemra thus far have been from Orencia.
› Verified 8 days ago
| Entity Name | Athens Medical Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982714358 PECOS PAC ID: 9537112685 Enrollment ID: O20050301000331 |
News Archive
Health pioneers BetterYou have welcomed new guidance by the National Institute for Health and Care Excellence (NICE) highlighting that many adults in Britain have low levels of vitamin D and that some exposure to sunlight can help to build this up.
Common anti-cholesterol drugs show promise for reducing the risk of Alzheimer's disease, a University of Southern California-led study of Medicare data reveals.
This study used U.S. population data to identify changes in the supply of primary care physicians across counties from 2005 to 2015 and the association with life expectancy and other outcomes.
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
Results from a study conducted by Majestic Research suggest that Bristol Myers Squibb's Orencia, Johnson & Johnson's Remicade, and Amgen's/Wyeth's Enbrel will forfeit share of the rheumatoid arthritis market to Roche's newly launched Actemra. Early switching data from Majestic's proprietary panel of rheumatologists indicates that Orencia may be the biggest loser of all, as 54% of switches to Actemra thus far have been from Orencia.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Scott A Jenkinson, DO 5450 Frantz Rd Ste 360, Dublin, OH 43016-4141 Ph: (614) 544-6155 | Scott A Jenkinson, DO 55 Hospital Dr, Athens, OH 45701-2302 Ph: (740) 566-4530 |
News Archive
Health pioneers BetterYou have welcomed new guidance by the National Institute for Health and Care Excellence (NICE) highlighting that many adults in Britain have low levels of vitamin D and that some exposure to sunlight can help to build this up.
Common anti-cholesterol drugs show promise for reducing the risk of Alzheimer's disease, a University of Southern California-led study of Medicare data reveals.
This study used U.S. population data to identify changes in the supply of primary care physicians across counties from 2005 to 2015 and the association with life expectancy and other outcomes.
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
Results from a study conducted by Majestic Research suggest that Bristol Myers Squibb's Orencia, Johnson & Johnson's Remicade, and Amgen's/Wyeth's Enbrel will forfeit share of the rheumatoid arthritis market to Roche's newly launched Actemra. Early switching data from Majestic's proprietary panel of rheumatologists indicates that Orencia may be the biggest loser of all, as 54% of switches to Actemra thus far have been from Orencia.
› Verified 8 days ago
Dr. Santi Kommareddi, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 75 Hospital Dr, Ste 370, Athens, OH 45701 Phone: 740-566-4530 |